Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib + Phesgo in PIK3CA-Mutated HER2-Positive Advanced Breast Cancer
NCT05894239Phase 3Recruiting
- Sponsor
- Roche
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of inavolisib in breast cancer, sponsored by Roche. Started Sep 2023; status: recruiting.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05894239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05894239.